The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function.
The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function.
复制标题
DOI:
10.1042/bj20121248
复制
发表时间:
2013-02-15
期刊:
影响因子:
--
通讯作者:
Ganapathy V
中科院分区:
文献类型:
--
作者:
Coothankandaswamy V;Elangovan S;Singh N;Prasad PD;Thangaraju M;Ganapathy V
SLC5A8 is a sodium-coupled transporter for monocarboxylates. Among its substrates are the HDAC inhibitors butyrate, propionate, and pyruvate. Expression of SLC5A8 is silenced in cancers via DNA methylation, and ectopic expression of SLC5A8 in cancer cells induces apoptosis in the presence of its substrates that are HDAC inhibitors. Here we show that ectopic expression of SLC5A8 in cancer cells translocates the anti-apoptotic protein survivin to plasma membrane through protein-protein interaction resulting in depletion of nuclear survivin and also decreases cellular levels of survivin through inhibition of transcription. These SLC5A8-induced changes in the location and levels of survivin result in cell cycle arrest, disruption of the chromosome passenger complex involved in mitosis, induction of apoptosis, and enhancement in chemosensitivity. These effects are seen independent of the transport function of SLC5A8 and histone acetylation status of the cell; in the presence of pyruvate, a SLC5A8 substrate and also an HDAC inhibitor, these effects are amplified. Ectopic expression of SLC5A8 in the breast cancer cell line MB231 inhibits the ability of the cell to form colonies in vitro and to form tumors in mouse xenografts in vivo. The suppression of survivin transcription occurs independent of HDAC inhibition, and the underlying mechanism is associated with decreased phosphorylation of STAT3. The observed effects are specific for survivin with no apparent changes in expression of other inhibitor-of-apoptosis proteins. These studies unravel a novel, hitherto unrecognized, mechanism for the tumor-suppressive role of a plasma membrane transporter independent of its transport function.